|Bid||59.58 x 1300|
|Ask||59.58 x 3200|
|Day's Range||59.51 - 59.72|
|52 Week Range||33.80 - 69.43|
|Beta (3Y Monthly)||1.94|
|PE Ratio (TTM)||37.21|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On Friday, August 9, Cambrex (NYSE: CBM ) will release its latest earnings report. Check out Benzinga's preview to understand the implications. Earnings and Revenue Cambrex EPS will likely be near 47 cents ...
Wall Street was set to open lower on Wednesday, as investors sought safety in gold and government bonds on worries about the impact of a long-drawn trade war on global economies. China's offshore yuan fell through the key level of 7-per-dollar mark after having recovered partly on Tuesday that had helped drive a 1% gain in the three main Wall Street indexes. Gold prices scaled a six-year peak.
Cambrex (NYSE: CBM ) shares are trading sharply higher after the company announced it will be acquired by the Permira Funds in a deal valued around $2.4 billion. Cambrex shareholders will receive $60 in ...
Wall Street's main indexes were on course to rise at the open on Wednesday, building on a recovery a day earlier, as President Donald Trump sought to play down the impact of a potentially drawn-out trade war on U.S. farmers and businesses. The three main Wall Street indexes jumped more than 1% on Tuesday after China stepped in to steady the yuan, easing fears that currencies would be the next weapon in the trade war between the United States and China. Shares of technology companies, including Apple Inc and chipmakers, were higher before the bell.
Private equity firm Permira Funds will buy Cambrex Corp for about $2 billion, the drug contract development and manufacturing company said on Wednesday. The all-cash offer of $60 per Cambrex share represents a 47% premium to the stock's Tuesday close. Cambrex, which provides drug developers with manufacturing and testing services, said that the deal is expected to close during the fourth quarter.
Shares of Cambrex Corp. rocketed 47% in toward a 10-month high in premarket trading Wednesday, after drug product and analytical services company agreed to be acquired in a deal valued at $2.4 billion including debt by an affiliate of the private-equity firm Permira. Under terms of the deal, Cambrex shareholders will receive $60 a share in cash for each Cambrex share they own, which represents a 47% premium to Tuesday's closing price of $40.78, and implies a market capitalization of about $2.02 billion. "This agreement is a strong endorsement of our strategy and represents significant value for our shareholders," said Cambrex Chief Executive Steve Klosk. Cambrex's stock has gained 8.0% year to date through Tuesday, while the S&P 500 has advanced 15.0%.
Shares of life-sciences company Cambrex surge after the company strikes a deal to be acquired by pharmaceutical-focused private-equity firm Permira funds for $2.4 billion, including debt.
Cambrex (CBM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 12.1% in 2019 (through May 30th). Conversely, hedge […]
Cambrex Corp NYSE:CBMView full report here! Summary * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is moderate for CBM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold CBM had net inflows of $924 million over the last one-month. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Basic Materials sector is rising. The rate of growth is weak relative to the trend shown over the past year, but is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology